Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Jon Koplik who wrote (1402)	11/12/1998 9:25:00 PM
From: marc ultra	Read Replies (1) \| Respond to of 2135

NCI response today National Cancer Institute FOR IMMEDIATE RELEASE November 12, 1998 FOR RESPONSE TO INQUIRIES NCI Press Office (301) 496-6641 Press Release NCI Continues to Conduct Research on Endostatin and Angiostatin In November 1997, scientists in the laboratory of Judah Folkman, M.D., of Children's Hospital and Harvard Medical School in Boston, Mass., published the results of experiments indicating that the compounds endostatin and angiostatin are potent anti-cancer agents in mice. Given the promising outcome of these experiments, the National Cancer Institute (NCI) has worked on confirming the results and preparing the compounds in a timely manner for studies in people.* Follow-up studies of endostatin have been under way for several months at NCI in collaboration with EntreMed, Inc., of Rockville, Md. Although the results of these investigations are still extremely preliminary, they show in some treatment groups that murine endostatin shows slight delays in the growth of a well-characterized lung tumor in laboratory mice, the same type of tumor and mouse used by Folkman's group. Others studies at EntreMed show delay in tumor growth using the human version of endostatin in mice. However, to date, NCI studies using either the mouse or human forms of endostatin have not produced the marked regression of these tumors in mice that Folkman's laboratory has reported. Scientists from NCI and Folkman's laboratory are working together to resolve the differences in their research results. Given these developments, NCI now will conduct additional technical and research studies that aim to define how to use the agent effectively in mice, the animal that was the basis for the original interest in endostatin. The process of angiogenesis and its role in tumor growth remain the focus of much research and clinical testing. More than a dozen agents aimed at controlling or treating cancer by inhibiting tumor blood vessels now are being tested in clinical trials sponsored by drug companies and NCI. People interested in information about ongoing trials listed in NCI's PDQ database may contact NCI's Cancer Information Service at 1-800-4-CANCER or search PDQ themselves via the Internet (http://cancertrials.nci.nih.gov -- under "more" choose Introduction, then choose "finding specific trials.") *Angiostatin is now under study primarily at Bristol Myers Squibb under an agreement with EntreMed. NCI, however, has agreed to produce an adequate supply of the compound for academic research purposes.